ArticleJournal of cancer research and clinical oncology2025
Limited survival benefit in patients diagnosed with glioblastoma post-2016: a SEER population based registry analysis.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiotherapy for High-Grade Gliomas in Adults and Children: A Systematic Review of Advances Published in the Second Half of 2023.International journal of molecular sciences · 2026Pooled it
- Trends in Treatment and Survival Among Patients with Glioblastoma in the United States from 2000 to 2020.Cancers · 2026Article
- Review
- Comprehensive analysis of mitochondria-associated genes in glioblastoma via single-cell and bulk RNA sequencing.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe EF14 clinical trial reported an improvement in median overall survival (OS) from 16.0 months to 20.9 months in patients with glioblastoma (GBM) who received treatment with tumor treating fields (TTFs). This study evaluates overall survival in a large population-based cohort of patients with GBM before and after FDA approval of TTFs in 2015.
methodsA total of 27,534 patients from the Surveillance, Epidemiology and End Results (SEER) database with GBM who underwent surgery and post-operative radiotherapy were grouped into three diagnosis periods: those diagnosed pre-temozolomide (2000-2004), those diagnosed post-temozolomide (2005-2015), and those diagnosed post-TTFs (2016-2020). Overall survival (OS) was calculated using the Kaplan-Meier method, and multivariate Cox regression models were employed to estimate hazard ratios (HR).
resultsGBM diagnosis in the post-TTFs period was associated with a median OS of 15 months (95% CI 14-15 months) compared to a median OS of 14 months (95% CI 14-14 months, p < 0.001) for GBM diagnosis in the post-temozolomide/pre-TTFs period. 24-months OS was 25.6% (95% CI 24.5-26.8%) in the post-TTFs period and 24.7% (95% CI 24.0-25.4%) in the post-temozolomide/pre-TTFs period. In a multivariate model accounting for clinical characteristics, diagnosis in the post-TTFs period as compared to the post-temozolomide/pre-TTFs period was significantly associated with OS (HR: 0.941, 95% CI 0.912-0.972, p < 0.001).
conclusionThis population-based cohort demonstrated minimal change in survival for patients diagnosed with GBM before and after FDA approval of TTFs in 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.